GeoVax Labs, Inc. — Q1 2017 Form 10-Q
Reporting period: Three months ended March 31, 2017; balance-sheet comparisons are with December 31, 2016. GeoVax is a clinical-stage vaccine developer. Its candidates are primarily in preclinical development, except its preventive HIV vaccine, which is in human trials. It reported no product sales; revenue consisted of government grant and contract reimbursements.
Financial results and position
| Metric | Q1 2017 / March 31, 2017 | Comparable period / prior date |
|---|---|---|
| Grant revenue | $295,735 | $47,600 in Q1 2016 |
| Research and development expense | $551,795 | $438,004 in Q1 2016 |
| General and administrative expense | $292,667 | $906,505 in Q1 2016 |
| Operating loss | $548,727 | $1,296,909 in Q1 2016 |
| Net loss | $548,341 | $1,296,279 in Q1 2016 |
| Basic and diluted loss per share | $0.01 | $0.04 in Q1 2016 |
| Cash and cash equivalents | $166,749 | $454,030 at Dec. 31, 2016 |
| Total assets | $303,677 | $610,217 at Dec. 31, 2016 |
| Current liabilities | $547,901 | $369,847 at Dec. 31, 2016 |
| Working capital | Deficit of $307,514 | Positive $174,532 at Dec. 31, 2016 |
| Stockholders’ equity | Deficit of $244,224 | Equity of $240,370 at Dec. 31, 2016 |
| Operating cash flow | Used $332,098 per cash-flow statement | Used $629,064 in Q1 2016 |
No product gross margin was reported. No debt or committed credit lines were disclosed. Cash decreased by $287,281 in Q1, including $4,350 of investing outflows and $49,167 of financing proceeds from warrant exercises. The company reported $867,911 in approved grant and contract funds available as of March 31, 2017.
Changes and notable items
- Net loss narrowed year over year, alongside substantially lower G&A costs. G&A excluding stock-based compensation fell to $284,747 from $428,913; the prior-year quarter included $469,799 of warrant-modification compensation expense.
- Grant revenue increased as reimbursable grant-supported costs were incurred. R&D expense rose year over year, primarily reflecting fluctuating grant-funded activity.
- During March, the company issued 983,334 common shares from warrant exercises for $49,167 net proceeds. Common shares outstanding were 56,218,567 at March 31; 58,718,567 were reported outstanding as of May 12.
- Subsequent to quarter-end, warrant exercises generated $100,000 in April. In May, GeoVax sold Series D convertible preferred stock for $1 million; the shares were initially convertible into approximately 66.7 million common shares, presenting significant potential dilution.
- Accrued salaries and directors’ fees included in current liabilities totaled $381,989 and were being deferred. Lease and other firm purchase obligations were approximately $339,000, including about $225,000 expected to be reimbursed under government grants.
Outlook, risks and contingencies
Management said cash resources and existing government funding commitments were expected to support planned operations through the end of 2017, but additional funding would be required thereafter. The filing states there is substantial doubt about the company’s ability to continue as a going concern beyond that period; management’s plans to obtain grants, contracts, equity financing or warrant proceeds do not alleviate that doubt. Funding may not be available on acceptable terms or at all, and failure to secure it could force program delays, reductions or termination.
GeoVax reported an NIAID contract of up to $7.8 million for production of a DNA vaccine component, and described ongoing and planned HIV vaccine studies. In March, it entered an agreement with American Gene Technologies for a planned Phase 1 trial using combined technologies; AGT was to fund the trial and pay GeoVax $95,000, expected in Q2 2017. No commercial rights or licenses had been granted under that collaboration as of the filing.
Product development, clinical outcomes, regulatory approvals, competition and access to capital are key uncertainties. The company said it does not expect product revenue for at least several years. Grant revenue varies with the timing of eligible expenditures. No legal proceedings or material changes to previously disclosed risk factors were reported. Management concluded disclosure controls were effective.
Important facts for investors to verify
- Cash-flow inconsistency: The cash-flow statement reports Q1 operating cash use of $332,098, while MD&A states $322,098; verify the correct amount. The cash-flow statement also supports the $332,098 figure.
- Whether grant availability and reimbursements arrive on schedule, and whether additional financing is secured to fund operations beyond 2017.
- The terms, conversion mechanics and potential dilution of the May Series D preferred financing, alongside the large outstanding warrant and preferred-share overhang.
- Whether deferred management compensation, vendor obligations and planned clinical work can be funded without disrupting operations.
- Progress and funding for the HIV programs and other vaccine candidates, including the AGT collaboration and NIAID-supported studies.